Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

1 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of pancreatic ductal adenocarcinoma, a type of cancer that begins in the ducts of the pancreas. The study will evaluate the safety, tolerability, and effectiveness of a treatment regimen called mFOLFIRINOX, which is a combination of several chemotherapy drugs, with or without an additional drug known as BNT321. BNT321 is a type of protein called a monoclonal antibody that targets specific cancer cells. The trial is designed for patients who have had a surgical procedure to remove the cancer, known as a curative resection.

The purpose of the study is to determine if adding BNT321 to the standard mFOLFIRINOX treatment improves outcomes for patients. The study will be conducted in two phases. In the first phase, the focus will be on assessing the safety of BNT321 when used with mFOLFIRINOX and determining the appropriate dose for the second phase. The second phase will compare the effectiveness of mFOLFIRINOX with BNT321 against mFOLFIRINOX alone in preventing the return of cancer after surgery.

Participants in the trial will receive the treatments through intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein. The study will monitor patients for any side effects and measure how long they remain free of cancer after treatment. The trial aims to provide valuable information on whether the addition of BNT321 can offer better protection against the recurrence of pancreatic cancer following surgery.

1 Joining the trial

Upon joining the trial, the patient will have already signed an informed consent form, indicating understanding and agreement to participate in the study.

The patient must meet specific health criteria, including a confirmed diagnosis of pancreatic ductal adenocarcinoma and a complete surgical resection of the tumor.

2 Initial assessment

The patient will undergo an initial assessment to confirm eligibility, which includes a review of medical history and current health status.

Laboratory tests will be conducted to ensure the patient meets the necessary health parameters for participation.

3 Phase I treatment

The patient will receive a combination of medications known as mFOLFIRINOX, which includes folinic acid, irinotecan hydrochloride, fluorouracil, and oxaliplatin, administered through intravenous infusion.

Additionally, the patient may receive BNT321, a human antibody, also administered as a solution for infusion.

The primary goal of this phase is to assess the safety and determine the recommended dose of BNT321 when combined with mFOLFIRINOX.

4 Phase II treatment

In this phase, the patient will continue to receive mFOLFIRINOX, with or without BNT321, based on randomization.

The focus is on evaluating the effectiveness of the treatment in preventing the return of cancer after surgery.

5 Regular monitoring

Throughout the trial, the patient will attend scheduled visits for health monitoring, including laboratory tests and imaging studies to assess the response to treatment.

The patient will be monitored for any side effects or adverse reactions to the medications.

6 Completion of treatment

Upon completion of the treatment cycles, the patient will undergo a final assessment to evaluate the overall health status and treatment outcomes.

The patient will continue to be monitored for any long-term effects or recurrence of the disease.

Who Can Join the Study?

You must sign a form that shows you understand and agree to participate in the study.
You should be willing and able to attend scheduled visits, follow the treatment plan, and adhere to any lifestyle restrictions required by the study.
You need to have an ECOG performance status of 0 to 1, which means you are fully active or have some symptoms but can still do light work.
If you are a man who is sexually active with a woman who can become pregnant, you must agree to use condoms with a sperm-killing agent and ensure your partner uses a highly effective form of birth control during the study and for a specified time after the last dose of the study drugs.
You must have a confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer.
You should have had a complete surgical removal of the tumor (R0 or R1 resection) between 21 and 84 days before starting the study medication. You also need to provide tumor tissue from the surgery or a biopsy.
You must not have any signs of cancer spread, such as in other organs or fluid buildup in the abdomen or around the lungs, based on a scan done within four weeks before starting the study medication.
If you are a man, you must agree not to donate sperm during the study and for a specified time after the last dose of the study drugs.
If you are a woman who can become pregnant, you must agree to use a highly effective form of birth control and ensure your male partner uses condoms with a sperm-killing agent during the study and for a specified time after the last dose of the study drugs. If you cannot use a highly effective method for medical reasons, using condoms with a sperm-killing agent is acceptable.
You must have fully recovered from surgery and be able to receive chemotherapy.
Your blood tests must show acceptable levels, including white blood cells, red blood cells, platelets, liver enzymes, bilirubin, kidney function, and protein levels.
If you are a woman who can become pregnant, you must have a negative pregnancy test at the start of the study. Women who are postmenopausal or permanently sterilized do not need to take this test.
You must agree to allow the collection of blood samples to study how the drug moves through your body.
If you are a woman who can become pregnant, you must agree not to donate eggs for assisted reproduction during the study and for a specified time after the last dose of the study drugs.
You must agree not to participate in another study involving an experimental drug during this study.
You must be over 18 years old or considered an adult according to local laws when you sign the consent form.

Who Cannot Join the Study?

Patients who have not had surgery to remove their pancreatic cancer.
Patients who have not been diagnosed with pancreatic ductal adenocarcinoma, a type of pancreatic cancer.
Patients who have not had their cancer completely or partially removed (R0 or R1 resection).
Patients who are not able to safely receive the study treatment.
Patients who are not in the age range specified for the study.
Patients who are not able to follow the study procedures or attend study visits.
Patients who are part of a vulnerable population that the study cannot safely include.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Institut Gustave Roussy	Villejuif	France
Medizinische Hochschule Hannover	Hanover	Germany
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France
Centre Hospitalier Universitaire De Lille	Lille	France
Technische Universitaet Dresden	Dresden	Germany

Other Sites

Site Name	City	Country
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)	Munich	Germany
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Universitario 12 De Octubre	Madrid	Spain
Hospital Quironsalud Barcelona	Barcelona	Spain
Odense University Hospital	Odense	Denmark
Charite Universitaetsmedizin Berlin KöR	Berlin	Germany
Universitaetsklinikum Mannheim GmbH	Mannheim	Germany
Hospital Universitario Fundacion Jimenez Diaz	Madrid	Spain
Hospital Universitario Quironsalud Madrid	Pozuelo De Alarcon	Spain
Medical Center – University Of Freiburg	Freiburg Im Breisgau	Germany
Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH	Ulm	Germany
Hopital Beaujon	Clichy	France
Institut de Cancérologie de l’Ouest	Saint-Herblain	France
Htvogf Hrggvmfj	Herlev	Denmark
Kdvvzwnq dej Ubzoxfqezjed Mpxpckcw Avo	Munich	Germany
Hyveazaj Vpec deunxcrc	Barcelona	Spain

Trial status

Country	Status	Recruitment Start
Denmark	Not yet recruiting	29.02.2024
France	Not yet recruiting	29.02.2024
Germany	Not yet recruiting	29.02.2024
Spain	Not yet recruiting	29.02.2024

Trial locations

Investigated drugs:

BNT321 is an investigational medication being studied for its potential use in treating pancreatic cancer. In this trial, it is being tested to see if it can be safely combined with another treatment regimen and to determine the best dose to use in future studies. The goal is to see if adding BNT321 can help improve outcomes for patients who have had surgery to remove pancreatic cancer.

mFOLFIRINOX is a combination of chemotherapy drugs used to treat pancreatic cancer. It includes several medications that work together to kill cancer cells and prevent them from growing. In this trial, mFOLFIRINOX is being used as a standard treatment to see if it is more effective when combined with BNT321 compared to using mFOLFIRINOX alone.

Pancreatic Ductal Adenocarcinoma – This is a type of cancer that begins in the ducts of the pancreas, which is an organ located behind the stomach. It is known for its aggressive nature and tendency to spread quickly to nearby organs. The disease often progresses silently, with symptoms appearing only in advanced stages, such as jaundice, weight loss, and abdominal pain. Surgical resection, where the tumor is removed, is a common approach when the cancer is detected early enough. However, even after surgery, there is a risk of recurrence, making ongoing monitoring and additional treatments necessary. The disease’s progression can vary, but it typically involves the growth of cancerous cells that can invade other parts of the body.

Trial ID:

2023-506014-47-00

Protocol code:

BNT321-02

NCT ID:

NCT06069778

Trial Phase:

Human Pharmacology (Phase I) – Other

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?